Posters

Ocular surface changes after trabeculectomy in men and women

Poster Details

First Author: A.Antonova RUSSIA

Co Author(s):                        

Abstract Details

Purpose:

Glaucoma is the leading cause of global irreversible blindness. Prevalence of glaucoma for population aged 40–80 years is 3.54%. In 2013, the number of people (aged 40–80 years) with glaucoma worldwide was estimated to be 64.3 million, increasing to 76.0 million in 2020 and 111.8 million in 2040 52.6 - 84% of patients receiving hypotensive (as monocomponent, so and multicomponent) therapy accompanies dry eye syndrome (DES).

Setting:

Study of the state of the ocular surface in patients with glaucoma before and after trabeculectomy (TE).

Methods:

The study involved 483 patients, of whom 359 patients were monitored for at least 6 months after surgery. Patients are divided into two groups: first group-232 women and second group-127 men. The average age of the group was 70.7± 7.3 years. Estimation of the main parameters was carried out before the operation, as well as 1, 3 and 6 months after TE. All patients had a standard ophthalmologic examination; Ocular Surface Disease Index (OSDI) definition. Additional research methods included Tear film Break Up Time (TBUT), Schirmer I test and Schirmer II test.

Results:

In the first group OSDI significantly decreased. The TBUT before TE, equal to 10,0±4,63 s, after 1, 3 and 6 months increased to 11±4,30 s. The Schirmer I in the preoperative period equals to 14,0±5,76 mm and after 6 months of the study 15,0±6,39 mm. In the second group OSDI decreased. The TBUT before TE equal to 11±5,34 s, increased 12±4,76 s after 1 and 3 months, 6 months up to 13±5,10 s. The Schirmer I in the preoperative period 14±6,01 mm and after 6 months of research presented - 15 ± 5.84 mm.

Conclusions:

There were no significant differences in ocular surface between men and women before and after TE. Improvement of the ocular surface among men and women is noted a month after the operation. The disappearance of the pharmacological load after TE is accompanied by a regression of the symptoms and signs of DED, which helps to improve the quality of life of glaucoma patients.

Financial Disclosure:

None